🍽️ meglumine,(prescription)

AI Engines For more Details: Perplexity Kagi Labs You

Diagnostic Imaging: Meglumine is commonly used as a contrast agent in diagnostic imaging procedures such as X-rays, CT scans, and MRI scans. It enhances the visibility of certain tissues and organs, allowing healthcare providers to obtain clearer images for the diagnosis and evaluation of various medical conditions, including injuries, tumors, and other abnormalities.
Treatment of Visceral Leishmaniasis: Glucantime, a formulation of meglumine antimoniate, is used for the treatment of visceral leishmaniasis, a parasitic infection caused by Leishmania species. Glucantime works by inhibiting the growth and replication of the parasite, thereby helping to eliminate the infection. It is administered intravenously and may be used in combination with other antileishmanial medications.
Metabolic Disorders: Meglumine has been investigated for its potential therapeutic effects in metabolic disorders such as diabetes mellitus. Some studies suggest that meglumine may have insulin-sensitizing properties and could potentially improve glucose metabolism. However, further research is needed to fully understand its role in the management of metabolic conditions.
Radioprotective Properties: There is some evidence to suggest that meglumine may possess radioprotective properties, meaning it could help protect cells and tissues from the damaging effects of ionizing radiation. This property has been studied in the context of radiation therapy for cancer and in radiation exposure scenarios, but its clinical significance and applications require further investigation.
Anti-inflammatory Effects: Meglumine has been investigated for its potential anti-inflammatory effects in various experimental models. It may modulate immune responses and inflammatory processes, which could have implications for the treatment of inflammatory conditions such as arthritis, inflammatory bowel disease, and autoimmune disorders. However, more research is needed to elucidate its mechanisms of action and therapeutic potential in these contexts.
Antiviral Activity: Cycloferon, a formulation containing meglumine acridone acetate, has been studied for its potential antiviral activity against a range of viruses, including herpes simplex virus, human immunodeficiency virus (HIV), and hepatitis viruses. It is believed to exert its antiviral effects by stimulating the immune system and enhancing the body's natural defense mechanisms. However, further clinical studies are needed to confirm its efficacy and safety for the treatment of viral infections.
Antioxidant Properties: Meglumine may possess antioxidant properties, which could help neutralize harmful free radicals and reduce oxidative stress in the body. This antioxidant activity has potential implications for various health conditions associated with oxidative damage, including neurodegenerative diseases, cardiovascular disorders, and aging-related processes.

;

Check for interactions on Supp.AI | 📚 PubMed Citations

Data Contradictions — Limits of Certainity

Impacted of meglumine,(prescription) On Probiotics

Rank	Probiotic	Impact
genus	Bifidobacterium	Increases

Bacteria Impacted by meglumine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?
📓 Direct Citations	Taxonomy	Rank	Effect
1	Bifidobacterium	genus	Increases
1	Collinsella tanakaei	species	Increases
1	Slackia piriformis	species	Increases

Impact of meglumine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition	Positive Impact	Negative Impact	Benefit Ratio Impact
Acne	0.6		0.6
ADHD	0.6	0.6	0
Allergic Rhinitis (Hay Fever)	0.6	0.6	0
Allergies	0.6	0.6	0
Allergy to milk products	0.6		0.6
Alzheimer's disease	0.6	0.6	0
Amyotrophic lateral sclerosis (ALS) Motor Neuron		0.6	-0.6
Ankylosing spondylitis		0.6	-0.6
Anorexia Nervosa		0.6	-0.6
Asthma	0.6	0.6	0
Atherosclerosis		0.6	-0.6
Atrial fibrillation	0.6	0.6	0
Autism	0.6	0.6	0
Autoimmune Disease	0.6	0.6	0
Brain Trauma	0.6	0.6	0
Breast Cancer		0.6	-0.6
Carcinoma	0.6	0.6	0
Celiac Disease	0.6		0.6
Cerebral Palsy		0.6	-0.6
Chronic Fatigue Syndrome	0.6	0.6	0
Cognitive Function	0.6	0.6	0
Colorectal Cancer	0.6	0.6	0
Constipation	0.6		0.6
COVID-19	0.6	0.6	0
Crohn's Disease	0.6	0.6	0
cystic fibrosis	0.6		0.6
Depression	0.6	0.6	0
Dermatomyositis	0.6		0.6
Eczema	0.6		0.6
Endometriosis		0.6	-0.6
Epilepsy	0.6	0.6	0
erectile dysfunction	0.6		0.6
Fibromyalgia	0.6	0.6	0
Functional constipation / chronic idiopathic constipation	0.6	0.6	0
gallstone disease (gsd)	0.6		0.6
Generalized anxiety disorder	0.6		0.6
Graves' disease	0.6	0.6	0
Gulf War Syndrome	0.6		0.6
Hashimoto's thyroiditis	0.6	0.6	0
Heart Failure	0.6		0.6
High Histamine/low DAO	0.6		0.6
hyperglycemia	0.6		0.6
Hyperlipidemia (High Blood Fats)		0.6	-0.6
hypertension (High Blood Pressure	0.6	0.6	0
Hypothyroidism	0.6		0.6
Hypoxia	0.6	0.6	0
IgA nephropathy (IgAN)	0.6		0.6
Inflammatory Bowel Disease	0.6	0.6	0
Intracranial aneurysms	0.6		0.6
Irritable Bowel Syndrome	0.6	0.6	0
ischemic stroke		0.6	-0.6
Liver Cirrhosis	0.6	0.6	0
Long COVID	0.6	0.6	0
Mast Cell Issues / mastitis	0.6		0.6
ME/CFS with IBS	0.6		0.6
ME/CFS without IBS	0.6		0.6
Metabolic Syndrome	0.6	0.6	0
Mood Disorders	0.6	0.6	0
Multiple Sclerosis	0.6	0.6	0
Multiple system atrophy (MSA)	0.6		0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic	0.6		0.6
NonCeliac Gluten Sensitivity	0.6	0.6	0
Obesity	0.6	0.6	0
obsessive-compulsive disorder	0.6		0.6
Osteoarthritis	0.6		0.6
Osteoporosis	0.6		0.6
Parkinson's Disease	0.6	0.6	0
Polycystic ovary syndrome	0.6	0.6	0
Postural orthostatic tachycardia syndrome	0.6		0.6
Premenstrual dysphoric disorder		0.6	-0.6
Psoriasis		0.6	-0.6
rheumatoid arthritis (RA),Spondyloarthritis (SpA)	0.6	0.6	0
Rosacea	0.6	0.6	0
Schizophrenia	0.6	0.6	0
Sjögren syndrome	0.6		0.6
Sleep Apnea		0.6	-0.6
Slow gastric motility / Gastroparesis	0.6		0.6
Stress / posttraumatic stress disorder	0.6	0.6	0
Systemic Lupus Erythematosus	0.6		0.6
Tic Disorder	0.6		0.6
Type 1 Diabetes	0.6		0.6
Type 2 Diabetes	0.6	0.6	0
Ulcerative colitis	0.6	0.6	0
Unhealthy Ageing	0.6		0.6
Vitiligo	0.6	0.6	0

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]